Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Treatment based on rising CA125 blood levels does not improve survival for recurrent ovarian cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.07.09
Views: 15208

Dr Gordon Rustin - Mount Vernon Cancer Center, UK

Gordon Rustin, MD, Mount Vernon Cancer Center, Hertfordshire, United Kingdom, speaking at ASCO 2009: Treatment Based on Rising CA125 Blood Levels Does Not Improve Survival for Recurrent Ovarian Cancer, Compared to Waiting for Symptoms to Arise: European researchers report that starting treatment early for an ovarian cancer relapse based on CA125 blood levels alone does not improve overall survival, compared with delaying treatment until symptoms arise.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation